PreGene Gets 140 Million Yuan in Series B

CAR-T immunotherapy developer PreGene announced that it has completed 140 million yuan in Series B financing and launched the Hong Kong stock IPO process. This round of financing is led by Haier Biomedical. Other investors include Huapont Pharm, Hunan Health and Elderly Industry Investment Fund,  as well as existing shareholder  Cash Capital continued to participate in the investment.

This round of financing will help the company's ongoing clinical trials of a number of new drugs. At the same time, it will quickly enrich the product pipeline, promote international layout including Europe and the United States, and achieve product launches as soon as possible. 

The head of Haier Biomedical’s investment said: “Prikin has been deeply involved in the field of cell and gene therapy for many years. The core team has rich management experience and R&D experience. The company has product pipeline layouts in hematological tumors, solid tumors and autoimmune diseases. There is a great synergy in the comprehensive treatment of medical tumors. I believe that Prekin will develop rapidly under the leadership of the team, and continue to introduce excellent tumor treatment products to benefit the majority of tumor patients."

Founded in 2012, PreGene is a world-leading cell and gene therapy innovative drug research and development company. Its product pipeline includes many leading products such as TCR-T, CAR-T, and stem cells. At present, BCMA CAR-T has obtained the first clinical trial license for CAR-T cell drugs in South China.

In addition, the company is also applying the US FDAIND for multiple products; in October 2020, PreGene and Guangzhou Lingsheng jointly signed an exclusive license agreement with Bone Therapeutics, a listed pharmaceutical company on the London Stock Exchange, to obtain its unique universal bone cell therapy The rights to the production, clinical development and commercialization of the platform drug ALLOB® in the Asia-Pacific region.

Haier Biomedical was founded to focus on design, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. Using the concept of IoT, the company has become a provider of comprehensive solutions for various biotechnological challenges. Operating globally, Haier Biomedical, the world’s only complete cold chain provider, has solutions storage for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.